GLP-1INGREDIENT TRENDSNEW CATEGORY
At SupplySide Global 2025, industry observers noted that nearly half of all exhibitor booths featured GLP-1 companion products. That is not a niche category signal. That is a market restructuring in real time.
GLP-1 receptor agonist medications — including the branded medications you've heard of — work by reducing appetite and slowing gastric emptying, leading users to consume roughly 20% fewer calories per day. This is effective for weight management but creates a downstream problem: with less food intake, users systematically underconsumeprotein, magnesium, vitamin D, calcium, B12, fiber, and other essential micronutrients. Supplement brands that recognized this gap early are now building category leadership in a segment with enormous headroom and relatively little competition from established incumbents.
The Nutritional Gap: What GLP-1 Users Actually Need
Understanding the companion supplement opportunity requires understanding the specific gaps GLP-1 medications create. This is not generic wellness — it's a clinically grounded nutritional support category with identifiable deficiencies.
| NUTRIENT GAP | WHY IT OCCURS | SUPPLEMENT FORM OPPORTUNITY |
|---|---|---|
| Protein | Reduced calorie intake often leads to insufficient protein consumption, accelerating lean muscle loss alongside fat loss | High-bioavailability protein concentrates; HMB for muscle preservation; creatine monohydrate for muscle retention during weight loss |
| Magnesium | Reduced food volume plus GI side effects (nausea, diarrhea) impair magnesium absorption and increase depletion rate | Glycinate and threonate forms for high bioavailability; concentrated dosing to compensate for reduced food intake |
| Vitamin D & Calcium | Calorie restriction reduces fat absorption, which limits fat-soluble vitamin uptake including D3 | D3+K2 formulations; emulsified vitamin D for enhanced absorption without food; calcium citrate (better absorbed than carbonate without a full meal) |
| B Vitamins | Reduced dietary diversity leads to B12, B6, folate deficits; GI changes affect intrinsic factor-dependent B12 absorption | Methylcobalamin B12 (more bioavailable than cyanocobalamin); comprehensive B-complex in methylated forms |
| Fiber & Prebiotics | GLP-1 users experience constipation (20-50% prevalence) and gut microbiome disruption from reduced fiber intake | Targeted prebiotic/fiber blends; the prebiotic segment saw a 78% increase in "GLP-1-friendly" claims between 2020–2024 |
| Electrolytes | Reduced food and fluid intake, plus GI side effects, create electrolyte depletion — especially sodium and potassium | Low-calorie electrolyte formulations without added sugars; sodium, potassium, magnesium blends in convenient formats |
Market Positioning: Two Distinct Strategies
Within the GLP-1 supplement landscape, two distinct positioning approaches have emerged, and brands should understand which lane they're playing in before making product development decisions.
Lane 1: GLP-1 Companion Products
These are products designed to support users while on GLP-1 medications — addressing the nutritional gaps, managing side effects, and preserving muscle mass during weight loss. This is the larger opportunity: the companion market has broad awareness, clinical backing, and a consumer that is actively seeking solutions to specific, identifiable problems. The prebiotic, high-protein, and concentrated micronutrient categories are the primary plays here.
Lane 2: Natural GLP-1 Boosters
A separate and growing positioning involves ingredients that may support natural GLP-1 secretion — including collagen peptides, citrus flavonoids, and specialized bioactive compounds. These position either as pharmaceutical alternatives for consumers who can't or won't take medications, or as adjunct support between medication cycles. This lane carries higher regulatory complexity (natural GLP-1 secretion claims must be carefully substantiated) but also higher consumer price tolerance.
What Winning Brands Are Doing Differently
The brands gaining early share in GLP-1 companion products share several common practices. First, they are creating concentrated, high-bioavailability formulations specifically designed for reduced-intake consumers — not repurposing existing product lines with a "GLP-1 friendly" label. Second, they are investing in clinical content marketing: educational assets that explain why GLP-1 users face specific nutritional gaps, rather than generic wellness messaging. Third, they are building retail and telehealth partnerships alongside DTC channels — because many GLP-1 users are accessing medications through telehealth platforms that are actively seeking nutrition support recommendations.
Nestlé Health Science moved in March 2025 with targeted high-protein and metabolic health solutions for this cohort — a signal that large CPG players have validated the opportunity. Smaller, more agile supplement brands still have a window to build category authority before major brands fully activate.
The Compliance Consideration
It is important to note what GLP-1 companion supplements are not: they are not drugs, they do not treat obesity or diabetes, and they are not adjunct therapies that can make disease claims. The regulatory environment around GLP-1 adjacent claims is actively watched. Brands making treatment or efficacy claims about GLP-1 medications themselves — rather than simply positioning their products as nutritional support for people with reduced caloric intake — are likely to attract FDA and FTC attention. The legal structure is straightforward: structure/function claims supported by competent and reliable scientific evidence, not disease treatment claims.
Track GLP-1 ingredient trends weekly
Shelf Intelligence tracks which GLP-1 companion ingredients are gaining search momentum, which brands are moving in the space, and what regulatory signals are emerging — every Monday morning.
Subscribe Now